A Single-Centre, Observational Study to Evaluate Immune Re- Sponse to Covid-19 Vaccines in Immunocompromised Patients with Haematological Disorders (COVAC-IC)

Authors: Chandra D , O’Mara L , Bailey L , Aspey M , Asaduzzaman Md , Banavathi K , Lea S , Bowler R , Prasangika J , Ogbolosingha A , Goddard S , Phillips N , Wasim F , Badugama B , Kamran N , Perera K , Bano F , Pillai S , Dyer P , Aquil M , Lewney K , Lee J , Remegoso A , Watts K and Karunanithi K

DOI: 10.23880/aii-16000177

Volume 5, Issue 2

Abstract

To evaluate immunological response to Covid-19 vaccines in immunocompromised haematology patients we compared total Anti-SARS-CoV-2 spike antibody and T cell response in45 immunocompromised haematology patients with 30 healthy adults following 2 doses of Covid-19 vaccine for 3 -5 months at 30-day intervals. We found, non - significant difference in T celland total Anti-SARS-CoV-2 S antibody response between study and control group patients. Conclusions: Though there was a non - significant difference in T cell and total Anti-SARS-CoV-2 S anti body response between immunocompromised patients and healthy controls this did not result in any severe infection or Covid-19 related mortality in our study cohort. We did not identify any patient-specific factor (age, gender), specific haematological condition or treatment as determinant of response. Covid-19 vaccination was well tolerated without major side effects in both groups.

Keywords: Covid-19 vaccines; Immunogenicity; Immunocompromised; Haematological disorders; safety; Efficacy COVACIC, ClinicalTrials.gov Identifier: NCT04805216

View PDF